Literature DB >> 3037206

Methotrexate for relapse of metastatic non-seminomatous germ-cell tumours.

C H Atkinson, A Horwich, M J Peckham.   

Abstract

Twelve patients with metastatic non-seminomatous germ-cell tumours who relapsed after 3-9 courses (median 7) of cis-platin containing combination chemotherapy, were treated with moderately high-dose methotrexate (1 g m-2) and folinic acid rescue. There was one partial response and the remaining eleven patients showed progression of disease. The patient that responded was one of two patients treated at the time of first relapse. It is concluded that methotrexate does not have a useful role in the salvage treatment of germ-cell tumours relapsing after cis-platin-containing chemotherapy or in patients who are primarily resistant to cis-platin-containing regimes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3037206     DOI: 10.1007/BF02934932

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  14 in total

1.  Chemotherapy for metastatic teratomas of the testis.

Authors:  D W Smithers
Journal:  Br J Urol       Date:  1972-04

Review 2.  The clinical pharmacology of methotrexate.

Authors:  J H Schornagel; J G McVie
Journal:  Cancer Treat Rev       Date:  1983-03       Impact factor: 12.111

3.  Chemotherapy of metastatic testis cancer. Results in 154 patients.

Authors:  A R Mackenzie
Journal:  Cancer       Date:  1966-10       Impact factor: 6.860

4.  Bleomycin combination chemotherapy in the management of testicular neoplasia.

Authors:  M L Samuels; P Y Holoye; D E Johnson
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

5.  Chemotherapy of disseminated testicular cancer. A random prospective study.

Authors:  L H Einhorn; S D Williams
Journal:  Cancer       Date:  1980-09-15       Impact factor: 6.860

6.  Further advances in the management of malignant teratomas of the testis and other sites.

Authors:  E S Newlands; R H Begent; G J Rustin; D Parker; K D Bagshawe
Journal:  Lancet       Date:  1983-04-30       Impact factor: 79.321

Review 7.  Establishment of cross-resistance profiles for new agents.

Authors:  F M Schabel; H E Skipper; M W Trader; W R Laster; D P Griswold; T H Corbett
Journal:  Cancer Treat Rep       Date:  1983-10

8.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

9.  Twenty years of anaplastic germ cell tumours.

Authors:  K D Bagshawe
Journal:  J R Soc Med       Date:  1984-01       Impact factor: 18.000

10.  The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP).

Authors:  M J Peckham; A Barrett; K H Liew; A Horwich; B Robinson; H J Dobbs; T J McElwain; W F Hendry
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640

View more
  2 in total

1.  Salvage therapy of germ cell tumours.

Authors:  A Horwich
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

2.  GAMEC--a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours.

Authors:  J Shamash; T Powles; W Ansell; Dan Berney; J Stebbing; K Mutsvangwa; P Wilson; S Asterling; S Liu; P Wyatt; S P Joel; R T D Oliver
Journal:  Br J Cancer       Date:  2007-07-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.